AAVXF:OTCMKTS
Abivax SA
US$139.00
0.00%
(0.00) 1D
7월 9일, 오전 9시 30분 1초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoAAVXF의 주요 통계 생성 중...
시가총액
68.10억
평균 거래량
0.00
거래량
0.00
52주 최고가
US$139.00
52주 최저가
US$71.26
베타
3.09
유통 주식수
8753.00만
직원 수
98
시가총액
68.10억
평균 거래량
0.00
거래량
0.00
52주 최고가
US$139.00
52주 최저가
US$71.26
베타
3.09
유통 주식수
8753.00만
직원 수
98
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA에 관한 정보